Burney Co. Cuts Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Burney Co. cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 89.2% in the 4th quarter, HoldingsChannel reports. The firm owned 6,529 shares of the medical equipment provider’s stock after selling 53,857 shares during the quarter. Burney Co.’s holdings in Lantheus were worth $584,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus during the third quarter worth about $25,000. Signaturefd LLC grew its position in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares during the period. Nkcfo LLC purchased a new stake in shares of Lantheus during the 2nd quarter worth approximately $47,000. UMB Bank n.a. raised its holdings in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the period. Finally, Kathleen S. Wright Associates Inc. purchased a new position in Lantheus in the third quarter valued at approximately $51,000. 99.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.10% of the stock is currently owned by insiders.

Lantheus Trading Down 0.1 %

Shares of Lantheus stock opened at $91.47 on Friday. The company’s 50-day moving average price is $89.72 and its 200-day moving average price is $99.85. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The company has a market cap of $6.36 billion, a price-to-earnings ratio of 15.22 and a beta of 0.46.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of recent research reports. The Goldman Sachs Group assumed coverage on Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. JMP Securities restated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday. Truist Financial reaffirmed a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.